Back to Search Start Over

Mid-p strategy versus ITV strategy in locally advanced lung cancer. A randomized phase II study

Authors :
Claude, L.
Isnardi, V.
Schiffler, C.
Metzger, S.
Martel-Lafay, Isabelle
Rit, Simon
Sarrut, David
Baudier, Thomas
Ayadi, M.
Rayet, Béatrice
Centre Léon Bérard [Lyon]
Imagerie Tomographique et Radiothérapie
Centre de Recherche en Acquisition et Traitement de l'Image pour la Santé (CREATIS)
Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon)
Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL)
Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Jean Monnet [Saint-Étienne] (UJM)-Hospices Civils de Lyon (HCL)-Institut National des Sciences Appliquées de Lyon (INSA Lyon)
Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Source :
ESTRO Annual Conference-Optimal radiotherapy for all, ESTRO Annual Conference-Optimal radiotherapy for all, Aug 2021, Madrid & Virtual, Spain
Publication Year :
2021
Publisher :
HAL CCSD, 2021.

Abstract

International audience; Purpose/Objective The overall survival (OS) of patients (pts) with non-resectable locally advanced non-small cell lung carcinoma (LA-NSCLC) is poor, in part due to insufficient local control (LC) using conformal irradiation techniques (RT). The personalization of the RT margins may impact the LC and the outcome. Internal Target Volume strategy (ITV) versus "Mid-position" strategy (Mid-p), was compared in a prospective non-comparative randomized monocentric phase II trial in NSCLC patients treated by definitive radiotherapy. Planning Target volumes and mean lung dose were previously reported as significantly reduced using the Mid-p strategy (DOI: 10.1259/bjr.20190692). We report here the clinical results. Material and Methods Eligible patients were randomized (2:1) to be treated with Mid-p or ITV strategies. Patients with proven LA-NSCLC, non-resected, non-metastatic treated by definitive RT could be included. The main objective was to evaluate the 1-year progression-free-survival (PFS) rate in the two arms. 36 pts were planned in the Mid-p arm, Fleming single-stage design (1-sided =0.1, 80% power, P0=30%, P1=50%). Secondary objectives were to evaluate 1-y and 2-y LC, OS and acute/middle term toxicity (NCI-CTCAE v4).Results 54 pts were randomized from 09/12 to 05/18. 3 patients finally did not receive radiotherapy and were excluded from the analysis. Median age was 65.2 y, 2/3 of the patients were male and had IIIA NSCLC stages, 31% received concomitant chemotherapy. 34 pts and 17 pts were included in the analysis in the Mid-p arm and ITV arm respectively. Median RT dose was 66 Gy in the Mid-p arm and 62 Gy in the ITV arm. Median PFS were 9.3 months and 10.3 months in the Mid-p arm and ITV arms respectively. 1-year PFS rate were 38% (1-sided CI95% = 25-) and 47% (CI95% = [27;[) in the Mid-p/ITV arm respectively. Efficacy in Mid-p arm is below that expected (starting hypothesis p0=30%, p1=50%). 2-year PFS rates were 15% (Mid-p) and 12% (ITV). 2-years LC rates were 65% (CI95% [48;81]) and 76% (CI95% [53;94]) in the Mid-p/ITV arms respectively. The analysis of the type of local failures (in field versus border of fields) is under analysis and will be available for the congress.No grade 4 or toxic deaths related to RT were reported. Grade 3 acute lung toxicity were reported in 12% and 23% in Mid-p and in ITV arms respectively. Grade 2 and Grade 3 late radiation fibrosis were reported in 29% and 15% respectively in the Mid-p arm, versus 23% and 29% using ITV strategy. Conclusion Two-year LC and PFS in LA-NSCLC seems similar in this non comparative Phase II randomized study using Mid-p or ITV strategies. The details of local relapses regarding RT fields and margins are under analysis and will be presented during the congress.Conflict of interest: this study was granted by Elekta.

Details

Language :
English
Database :
OpenAIRE
Journal :
ESTRO Annual Conference-Optimal radiotherapy for all, ESTRO Annual Conference-Optimal radiotherapy for all, Aug 2021, Madrid & Virtual, Spain
Accession number :
edsair.dedup.wf.001..b7daa9d5d908451b87f68a6720e66815